371 related articles for article (PubMed ID: 24286707)
1. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice.
Hoyer FF; Khoury M; Slomka H; Kebschull M; Lerner R; Lutz B; Schott H; Lütjohann D; Wojtalla A; Becker A; Zimmer A; Nickenig G
J Mol Cell Cardiol; 2014 Jan; 66():126-32. PubMed ID: 24286707
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice.
Lenglet S; Thomas A; Soehnlein O; Montecucco F; Burger F; Pelli G; Galan K; Cravatt B; Staub C; Steffens S
Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):215-23. PubMed ID: 23241405
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
4. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
5. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
6. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages.
Sun YX; Tsuboi K; Zhao LY; Okamoto Y; Lambert DM; Ueda N
Biochim Biophys Acta; 2005 Oct; 1736(3):211-20. PubMed ID: 16154384
[TBL] [Abstract][Full Text] [Related]
7. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.
Kwilasz AJ; Abdullah RA; Poklis JL; Lichtman AH; Negus SS
Behav Pharmacol; 2014 Apr; 25(2):119-29. PubMed ID: 24583930
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality.
Naidu PS; Varvel SA; Ahn K; Cravatt BF; Martin BR; Lichtman AH
Psychopharmacology (Berl); 2007 May; 192(1):61-70. PubMed ID: 17279376
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.
Justinova Z; Mangieri RA; Bortolato M; Chefer SI; Mukhin AG; Clapper JR; King AR; Redhi GH; Yasar S; Piomelli D; Goldberg SR
Biol Psychiatry; 2008 Dec; 64(11):930-7. PubMed ID: 18814866
[TBL] [Abstract][Full Text] [Related]
10. The effects of fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on lipopolysaccharide-induced airway inflammation in mice.
Abohalaka R; Bozkurt TE; Nemutlu E; Onder SC; Sahin-Erdemli I
Pulm Pharmacol Ther; 2020 Jun; 62():101920. PubMed ID: 32416152
[TBL] [Abstract][Full Text] [Related]
11. The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms.
Bosier B; Muccioli GG; Lambert DM
Br J Pharmacol; 2013 Jun; 169(4):794-807. PubMed ID: 22970888
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells.
Li H; Wood JT; Whitten KM; Vadivel SK; Seng S; Makriyannis A; Avraham HK
Br J Pharmacol; 2013 Oct; 170(3):489-505. PubMed ID: 23347118
[TBL] [Abstract][Full Text] [Related]
14. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.
Scherma M; Medalie J; Fratta W; Vadivel SK; Makriyannis A; Piomelli D; Mikics E; Haller J; Yasar S; Tanda G; Goldberg SR
Neuropharmacology; 2008 Jan; 54(1):129-40. PubMed ID: 17904589
[TBL] [Abstract][Full Text] [Related]
15. Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization.
Grieco M; De Caris MG; Maggi E; Armeli F; Coccurello R; Bisogno T; D'Erme M; Maccarrone M; Mancini P; Businaro R
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299330
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
17. Effects of the fatty acid amide hydrolase inhibitor URB597 on coping behavior under challenging conditions in mice.
Haller J; Aliczki M; Pelczer KG; Spitzer K; Balogh Z; Kantor S
Psychopharmacology (Berl); 2014 Feb; 231(3):593-601. PubMed ID: 24037493
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells.
Winkler K; Ramer R; Dithmer S; Ivanov I; Merkord J; Hinz B
Oncotarget; 2016 Mar; 7(12):15047-64. PubMed ID: 26930716
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
Celorrio M; Fernández-Suárez D; Rojo-Bustamante E; Echeverry-Alzate V; Ramírez MJ; Hillard CJ; López-Moreno JA; Maldonado R; Oyarzábal J; Franco R; Aymerich MS
Brain Behav Immun; 2016 Oct; 57():94-105. PubMed ID: 27318096
[TBL] [Abstract][Full Text] [Related]
20. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat.
Cippitelli A; Cannella N; Braconi S; Duranti A; Tontini A; Bilbao A; Defonseca FR; Piomelli D; Ciccocioppo R
Psychopharmacology (Berl); 2008 Jul; 198(4):449-60. PubMed ID: 18446329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
